Skip to content
Tanezumab
Tanezumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against beta-nerve growth factor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02B: Other analgesics and antipyretics in atc
— N02BG: Other analgesics and antipyretics in atc
— N02BG12: Tanezumab
HCPCS
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoarthritisD010003EFO_0002506M15-M19—212——14
Low back painD017116HP_0003419M54.5132——6
ArthritisD001168EFO_0005856M05-M14—15——6
Knee osteoarthritisD020370EFO_0004616M17—23——5
Hip osteoarthritisD015207EFO_1000786M16—14——5
PainD010146EFO_0003843R52—11——2
Neoplasm metastasisD009362EFO_0009708—11——2
Chronic painD059350HP_0012532——1——1
Cancer painD000072716G89.3——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Interstitial cystitisD018856EFO_1000869N30.112———3
Diabetic neuropathiesD003929EFO_1000783—1———1
NeurilemmomaD009442EFO_0000693—1———1
Chronic pancreatitisD050500EFO_0000342K86.1—1———1
ProstatitisD011472EFO_0003830N41—1———1
EndometriosisD004715EFO_0001065N80—1———1
Postherpetic neuralgiaD051474—1———1
Palliative careD010166—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Spine osteoarthritisD055013EFO_10007871————1
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTANEZUMAB
INNtanezumab
Description
Tanezumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)TANEZUMAB
Structure (InChI/SMILES or Protein Sequence)
>4EDW:H|tanezumab Fab heavy chain QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSL KLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKTSHHHHHHG >4EDW:L|tanezumab Fab light chain DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQP EDIATYYCQQEHTLPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB4EDW
CAS-ID880266-57-9
RxCUI—
ChEMBL IDCHEMBL2108567
ChEBI ID—
PubChem CID—
DrugBankDB12335
UNII IDEQL0E9GCX1 (ChemIDplus, GSRS)
Target
Agency Approved
NGF
NGF
Organism
Homo sapiens
Gene name
NGF
Gene synonyms
NGFB
NCBI Gene ID
4803
Protein name
beta-nerve growth factor
Protein synonyms
nerve growth factor (beta polypeptide), nerve growth factor, beta subunit, pro-nerve growth factor long
Uniprot ID
Q9UKL8
Mouse ortholog
Ngf (18049)
beta-nerve growth factor (Q6LDB7)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 689 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
55 adverse events reported
View more details